Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.

Dong Y, Yang X, Wong O, Zhang X, Liang Y, Zhang Y, Wong W, Nong L, Liao Q, Li T.

Hum Pathol. 2012 Aug;43(8):1197-205. doi: 10.1016/j.humpath.2011.08.021. Epub 2011 Dec 30.

PMID:
22209294
2.

[Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].

Yang X, Dong Y, Zhang XM, Liang Y, Zhang Y, Meng YT, Wang Y, Wang W, Nong L, Li T, Liao QP.

Zhonghua Bing Li Xue Za Zhi. 2011 Dec;40(12):799-804. Chinese.

PMID:
22336203
3.

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

Catasus L, Gallardo A, Cuatrecasas M, Prat J.

Mod Pathol. 2009 Apr;22(4):522-9. doi: 10.1038/modpathol.2009.5. Epub 2009 Feb 20.

4.

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 27;16(1):R13. doi: 10.1186/bcr3606.

5.

PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.

McIntyre JB, Nelson GS, Ghatage P, Morris D, Duggan MA, Lee CH, Doll CM, Köbel M.

Gynecol Oncol. 2014 Jan;132(1):188-93. doi: 10.1016/j.ygyno.2013.11.015. Epub 2013 Nov 19.

PMID:
24262879
6.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.

Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2.

7.

Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.

Mori N, Kyo S, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M.

Cancer Sci. 2007 Dec;98(12):1881-8. Epub 2007 Oct 9.

8.

Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.

Zhang X, Dong Y, Ti H, Zhao J, Wang Y, Li T, Zhang B.

Hum Pathol. 2013 Nov;44(11):2571-80. doi: 10.1016/j.humpath.2013.07.002. Epub 2013 Sep 24.

PMID:
24071015
9.

PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.

Konopka B, Janiec-Jankowska A, Kwiatkowska E, Najmoła U, Bidziński M, Olszewski W, Goluda C.

Hum Pathol. 2011 Nov;42(11):1710-9. doi: 10.1016/j.humpath.2010.01.030. Epub 2011 Apr 29.

PMID:
21531001
10.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

11.

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.

Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K; ANECS, Akslen LA, Claes B, Vergote I, Moerman P, Van Robays J, Marcickiewicz J, Salvesen HB, Spurdle AB, Amant F.

Gynecol Oncol. 2013 Feb;128(2):327-34. doi: 10.1016/j.ygyno.2012.11.037. Epub 2012 Dec 4.

PMID:
23219661
12.

[Correlations of p-AKT with PTEN, P53, HER-2 expressions in endometrial carcinoma and their relationship with patient survival].

Zhang XM, Liang Y, Dong Y, Zhang Y, Wang Y, Meng YT, Li T.

Beijing Da Xue Xue Bao Yi Xue Ban. 2012 Feb 18;44(1):135-41. Chinese.

13.

Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.

Catasus L, D'Angelo E, Pons C, Espinosa I, Prat J.

Mod Pathol. 2010 May;23(5):694-702. doi: 10.1038/modpathol.2010.44. Epub 2010 Feb 19.

14.

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.

Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.

Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.

PMID:
23728071
15.

Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.

Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H.

PLoS One. 2015 Mar 27;10(3):e0120511. doi: 10.1371/journal.pone.0120511. eCollection 2015.

16.

PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.

Abe A, Minaguchi T, Ochi H, Onuki M, Okada S, Matsumoto K, Satoh T, Oki A, Yoshikawa H.

Hum Pathol. 2013 Feb;44(2):199-207. doi: 10.1016/j.humpath.2012.05.005. Epub 2012 Sep 3.

PMID:
22955107
17.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

18.

Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.

Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, Nakazawa M, Nobuoka T, Kawayama M, Mikami M, Matsuno T, Hasegawa T, Hirata K, Imai K, Shinomura Y.

World J Gastroenterol. 2012 Dec 7;18(45):6577-86. doi: 10.3748/wjg.v18.i45.6577.

19.

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.

Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R.

JAMA Oncol. 2016 Dec 1;2(12):1565-1573. doi: 10.1001/jamaoncol.2016.0891.

PMID:
27388585
20.

Alternate molecular genetic pathways in ovarian carcinomas of common histological types.

Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, Swisher EM.

Hum Pathol. 2007 Apr;38(4):607-13. Epub 2007 Jan 29.

PMID:
17258789

Supplemental Content

Support Center